Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
1. A method of treating breast cancer or colon cancer, the method comprising administering a therapeutically effective amount of a monoclonal antibody that specifically binds to a non-ligand binding region of the extracellular domain of human NOTCH1, wherein the non-ligand binding region comprises epidermal growth factor (EGF) repeats 1-10 or EGF repeats 13-36.
2. The method of claim 1 , wherein the antibody is a chimeric antibody.
3. The method of claim 1 , wherein the antibody is a humanized antibody.
4. The method of claim 1 , wherein the antibody is a human antibody.
5. The method of claim 1 , wherein the antibody inhibits growth of tumor cells.
6. The method of claim 1 , wherein the antibody is an antagonist of human NOTCH 1.
7. The method of claim 1 , wherein the non-ligand binding region comprises EGF repeats 1-10.
8. The method of claim 7 , wherein the non-ligand binding region comprises EGF repeat 4.
9. The method of claim 1 , wherein the non-ligand binding region comprises EGF repeats 13-36.
10. The method of claim 9 , wherein the non-ligand binding region comprises EGF repeat 13.
11. The method of claim 1 , wherein the antibody comprises:
(a) a heavy chain CDR1 comprising SSYTMS (SEQ ID NO:12), a heavy chain CDR2 comprising YIDYGGDFTSYSDAIRG (SEQ ID NO:13), and a heavy chain CDR3 comprising RRYDAMDY (SEQ ID NO:14); and
(b) a light chain CDR1 comprising SASQAISNYLN (SEQ ID NO:15), a light chain CDR2 comprising YTTNLHS (SEQ ID NO:16), and a light chain CDR3 comprising QQYSKFPWT (SEQ ID NO:17).
12. The method of claim 1 , wherein the antibody is 13M57.
13. The method of claim 1 , wherein the antibody is conjugated to a cytotoxic moiety.
14. The method of claim 1 , wherein the antibody is administered with at least one additional therapeutic agent.
15. The method of claim 14 , wherein the additional therapeutic agent is a chemotherapeutic agent.
16. The method of claim 15 , wherein the chemotherapeutic agent is paclitaxel, oxaliplatin, or irinotecan.
17. The method of claim 14 , wherein the additional therapeutic is a second antibody.
18. The method of claim 1 , wherein the antibody is administered with radiation therapy.